{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-24-000067","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.933034+00:00","generated_at":"2026-05-30T03:34:47.589150+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elicio reports ELI-002 Phase 1 data: T cell responses correlate with DFS; Phase 2 enrollment expected Q4 2024","bullets":["All 12 evaluable patients showed mKRAS-specific T cell responses; RP2D group had 12-fold higher median response vs 1.4 mg group.","T cell response magnitude correlated with DFS: lowest quartile mDFS 3.1 months (p=0.0027), top three quartiles not yet reached.","Antigen spreading in 100% of RP2D-treated patients (n=6); T cells targeted 67.5% of patient-specific neoantigens.","ELI-002 remains safe and well-tolerated; no dose-limiting toxicities or cytokine release syndrome observed.","Phase 2 enrollment expected to complete in Q4 2024; interim event-driven DFS analysis expected H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-24-000067","json":"https://secwatch.observer/filing/0001601485-24-000067.json","markdown":"https://secwatch.observer/filing/0001601485-24-000067.md","text":"https://secwatch.observer/filing/0001601485-24-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000067/0001601485-24-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000067/angn-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:34:47.589150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}